Aria F. Olumi, MD

Beth Israel Deaconess Medical Center

Academic Titles

Janet & William DeWolf endowed Professor, Surgery, Harvard Medical School

Research Program Affiliation

Member, Kidney Cancer

Member, Prostate Cancer

Research Abstract

TRAIL, a recently discovered member of the TNF superfamily of cytokines, may be a useful apoptotic-inducing treatment for prostate cancer. However, better understanding the molecular pathways that render a cell TRAIL-sensitive (PC3 and DU145 cells) vs. TRAIL-resistant (LNCaP cells) is crucial in order to selectively offer TRAIL to patients who would maximally benefit from the drug. The focus of my lab is to delineate the molecular mechanisms between TRAIL-resistant and TRAIL-sensitive prostate cancer cells.